A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis

In this phase 2 open-label randomized study, 31 patients with intermediate-2 or high-risk myelofibrosis received fedratinib 300, 400 or 500 mg once daily in consecutive 4-week cycles. Mean spleen volume reductions at 12 weeks (primary end point) were 30.3% (300 mg), 33.1% (400 mg) and 43.3% (500 mg)...

Descripción completa

Detalles Bibliográficos
Autores principales: Pardanani, A, Tefferi, A, Jamieson, C, Gabrail, N Y, Lebedinsky, C, Gao, G, Liu, F, Xu, C, Cao, H, Talpaz, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558588/
https://www.ncbi.nlm.nih.gov/pubmed/26252788
http://dx.doi.org/10.1038/bcj.2015.63

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558588/
https://www.ncbi.nlm.nih.gov/pubmed/26252788
http://dx.doi.org/10.1038/bcj.2015.63

Ejemplares similares